|
Jan 4
|
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
|
|
Jan 3
|
Collegium Provides 2024 Financial Guidance
|
|
Dec 23
|
Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells Company Shares
|
|
Dec 21
|
Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells 68,768 Shares
|
|
Dec 14
|
Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%
|
|
Nov 30
|
Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...
|
|
Nov 27
|
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
|
|
Nov 9
|
Collegium Announces $25 Million Accelerated Share Repurchase Program
|
|
Nov 9
|
Should You Be Worried About Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 5.0% Return On Equity?
|
|
Nov 8
|
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
|
|
Nov 8
|
Collegium to Participate in Upcoming Investor Conferences
|
|
Nov 7
|
Collegium Reports Third Quarter 2023 Financial Results
|
|
Nov 1
|
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Aug 28
|
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
|
|
Aug 24
|
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
|
|
Apr 27
|
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
|